Ginsenoside Rg1 in the treatment of nonalcoholic fatty liver disease
10.12092/j.issn.1009-2501.2020.01.013
- VernacularTitle: 人参皂苷Rg1治疗非酒精性脂肪肝的研究进展
- Author:
Guiming LI
1
Author Information
1. Department of Cadre Health, First People's Hospital of Yunnan Province
- Publication Type:Journal Article
- Keywords:
Endoplasmic reticulum stress;
Ginsenoside Rg1;
Insulin resistance;
Nonalcoholic fatty liver;
Oxidative stress
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2020;25(1):87-93
- CountryChina
- Language:Chinese
-
Abstract:
Nonalcoholic fatty liver (NAFLD) is a substantial pathological change of the liver caused by no excessive alcohol intake or genetic predisposition. It can further develop into non-alcoholic steatohepatitis, liver cirrhosis, hepatocellular carcinoma, liver failure. Studies have shown that non-alcoholic fatty liver is also closely related to a variety of metabolic diseases, such as type 2 diabetes mellitus(T2DM), hypertension, cardiovascular disease and so on. However, its pathogenesis is not clear, and there is a lack of drugs for clinical treatment. Ginsenoside Rg1 has a wide range of effects, such as antioxidation, anti-aging, anti-inflammatory reaction, auxiliary treatment of diabetes and so on. In this paper, the pathogenesis of NAFLD and the research progress of Rg1 in NAFLD are reviewed.
